CereVasc today announced a partnership with LianMedical to bring CereVasc’s technology to Asia.
The partnership aims to accelerate the introduction of breakthrough medical technologies to markets in China, Hong Kong, Taiwan and Macaw. The partnership will focus on bringing CereVasc’s eShunt system and related products to the region.
“We are very excited by the opportunity for our products to improve the standard of care for patients with hydrocephalus in these territories and believe we have identified the ideal partner in LianMedical to support these expansion efforts,” CereVasc CEO and President Dan Levangie said in a news release.
LianMedical, headquartered in Shanghai, develops and commercializes medical devices for neurology and cardiovascular medicine.
“There is a significant unmet clinical need in hydrocephalus treatment in Asia. The eShunt System is an innovation that can potentially revolutionize the standard of care and benefit thousands of patients. We are excited to partner with Dan and his team to capitalize on this significant opportunity,” LianMedical CEO Luxin Wang said.
The eShunt system has percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH). It includes an endovascularly implantable cerebral spinal fluid shunt and delivery components that are designed to treat CH without invasive surgery. It is currently investigational and unavailable for sale within or outside the U.S.
